This pharma company just announced its intention to acquire Biscayne Neurotherapeutics, a privately-held company developing a novel treatment for epilepsy.
Supernus Pharmaceuticals, Inc. (SUPN)
From Cabot Undervalued Stocks Advisor
Supernus Pharmaceuticals, Inc. (SUPN) focuses on the development and commercialization of products for the treatment of central nervous system diseases and psychiatric disorders, including epilepsy, migraine and ADHD.
The stock rose last week, along with earnings estimates, possibly in reaction to the company’s presentation at the 2018 Wells Fargo Healthcare Conference, or from its September 5 recommendation in Investor’s Business Daily, or from news that Supernus successfully defended three patents for Oxtellar XR Orange Book, a treatment for epilepsy. (Investors may access the conference presentation via the company’s website.)
SUPN is an undervalued, small-cap aggressive growth stock. Analysts now expect EPS to increase 57.1% and 30.3% in 2018 and 2019. The corresponding P/Es are 24.3 and 18.7. SUPN could reach anywhere from 51 to 55 in the coming days. I would expect additional capital appreciation later this year. Strong Buy.
Crista Huff, Cabot Undervalued Stocks Advisor, www.cabotwealth.com, 978-745-5532, September 11, 2018